LAKE OSWEGO, Ore.--(BUSINESS WIRE)--Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today its support for the guidance policy unveiled last week by the National AIDS Control Council (NACC) of Kenya gives Kenyans personal control over their HIV testing and encourages them to use non-invasive tests such as HIV-1/2 OMT (oral fluid) rapid tests. Calypte has provided Kenya, through the National AIDS and STD Control Program (NASCOP) of the Ministry of Health, 10,000 Aware® HIV-1/2 OMT (oral fluid) rapid tests which will be available to the public.
